Menu
← Oncology Approval Tracker
FDA DECISION ·
Penpulimab-kcqx
penpulimab-kcqx · Akeso Biopharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
With gemcitabine and either cisplatin or carboplatin as first-line therapy for adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.
LAMPGEN ANALYSIS
Why it matters
The approval introduced penpulimab with platinum-based chemotherapy in first-line recurrent or metastatic non-keratinizing disease.
What research teams should watch
Confirm histology and allow documentation of the platinum choice and supportive care needs across treatment sites.
PRIMARY RECORDS